用于艰难梭菌感染的微生物组疗法
Microbiome Therapeutics for Clostridioides difficile Infection.
作者信息
Lucky Christine W, Kelly Brendan J, Kwon Jennie H, Woodworth Michael H, Medernach Rachel L
机构信息
Division of Infectious Diseases, Department of Medicine, Rush University, 600 South Paulina Street, Armour Academic Center, Suite 143, Chicago, IL 60612, USA.
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, 731 Blockey Hall, Philadelphia, PA 19104, USA; Division of Infectious Diseases, Department of Epidemiology, University of Pennsylvania, Philadelphia, PA, USA; Division of Infectious Diseases, Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Infect Dis Clin North Am. 2025 Aug 11. doi: 10.1016/j.idc.2025.07.007.
Microbiota-based therapies are used increasingly for the treatment and prevention of Clostridioides difficile infection (CDI), particularly in cases of recurrent CDI (rCDI). This review discusses the different types of microbiota-based therapies, including fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products. The authors present efficacy data regarding clinical use in rCDI and highlight the unique aspects of each product.
基于微生物群的疗法越来越多地用于艰难梭菌感染（CDI）的治疗和预防，特别是在复发性CDI（rCDI）的病例中。本综述讨论了不同类型的基于微生物群的疗法，包括粪便微生物群移植、粪便微生物群产品和活生物治疗产品。作者展示了关于rCDI临床应用的疗效数据，并强调了每种产品的独特之处。
Zotero 插件